Interestingly, in contrast to the evidence that elevation in m6A levels contributes to cardiac injury in many cardiac diseases, our results demonstrated that Mettl14 protected against cardiac I/R injury by employing gain- and loss-of-functional assay. This evidence concerns the gene METTL14 and heart disorder.